ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
IPO Year: 2018
Exchange: NASDAQ
Website: aslanpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/9/2021 | $8.00 | Buy | Jefferies |
Jefferies initiated coverage of ASLAN Pharmaceuticals with a rating of Buy and set a new price target of $8.00
HC Wainwright & Co. reiterated coverage of ASLAN Pharmaceuticals with a rating of Buy and set a new price target of $8.00 from $5.00 previously